Correlation of KRAS status with clinical outcome in patients (pts) with metastatic colorectal cancer (mCRC) treated first-line with FOLFOX6+cetuximab (FX plus C) or FOLFIRI plus cetuximab (FF plus C): The CECOG/CORE1.2.001 trial

被引：0
|
作者：
Koza, I., Sr. [1 ,2 ,3 ,4 ,5 ,6 ,7 ]
Wrba, F. [1 ,2 ,3 ,4 ,5 ,6 ,7 ]
Vrbanec, D. [1 ,2 ,3 ,4 ,5 ,6 ,7 ]
Ocvirk, J. [1 ,2 ,3 ,4 ,5 ,6 ,7 ]
Ciuleanu, T. E. [1 ,2 ,3 ,4 ,5 ,6 ,7 ]
Beslija, S. [1 ,2 ,3 ,4 ,5 ,6 ,7 ]
Papamichael, D. [1 ,2 ,3 ,4 ,5 ,6 ,7 ]
Messinger, D. [1 ,2 ,3 ,4 ,5 ,6 ,7 ]
Zielinski, C. C. [1 ,2 ,3 ,4 ,5 ,6 ,7 ]
Brodowicz, T. [1 ,2 ,3 ,4 ,5 ,6 ,7 ]
机构：
[1] NCI, Bratislava, Slovakia
[2] Med Univ Vienna, Vienna, Austria
[3] Univ Hosp Rebro, Zagreb, Croatia
[4] Inst Oncol, Ljubljana, Slovenia
[5] Univ Med Cluj Napoca, Cluj Napoca, Romania
[6] Univ Sarajevo, Ctr Clin, Sarajevo 71000, Bosnia & Herceg
[7] Bank Cyprus Oncol Ctr, Nicosia, Cyprus
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2009年 / 27卷 / 15期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
4055
引用
收藏
页数：2
相关论文
共 50 条
  • [1] RELATIONSHIP BETWEEN KRAS STATUS AND EFFICACY OF FOLFOX6+CETUXIMAB OR FOLFIRI plus CETUXIMAB IN FIRST-LINE TREATMENT OF PATIENTS WITH METASTATIC COLORECTAL CANCER (MCRC): THE CECOG/CORE1.2.001 TRIAL
    Ocvirk, J.
    Vrbanec, D.
    Beslija, S.
    Koza, I
    Ciuleanu, T.
    Papamichael, D.
    Wrba, F.
    Messinger, D.
    Zielinski, C.
    Brodowicz, T.
    ANNALS OF ONCOLOGY, 2009, 20 : 17 - 17
  • [2] Cetuximab plus FOLFOX6 or FOLFIRI in metastatic colorectal cancer: CECOG trial
    Ocvirk, Janja
    Brodowicz, Thomas
    Wrba, Fritz
    Ciuleanu, Tudor E.
    Kurteva, Galina
    Beslija, Semir
    Koza, Ivan
    Zsuzsanna Papai
    Messinger, Diethelm
    Yilmaz, Ugur
    Zsolt Faluhelyi
    Yalcin, Suayib
    Papamichael, Demetris
    Miklos Wenczl
    Mrsic-Krmpotic, Zrinka
    Shacham-Shmueli, Einat
    Vrbanec, Damir
    Esser, Regina
    Scheithauer, Werner
    Zielinski, Christoph C.
    WORLD JOURNAL OF GASTROENTEROLOGY, 2010, 16 (25) : 3133 - 3143
  • [3] Cetuximab plus FOLFOX6 or FOLFIRI in metastatic colorectal cancer: CECOG trial
    Janja Ocvirk
    Thomas Brodowicz
    Fritz Wrba
    Tudor E Ciuleanu
    Galina Kurteva
    Semir Beslija
    Ivan Koza
    Zsuzsanna Pápai
    Diethelm Messinger
    Ugur Yilmaz
    Zsolt Faluhelyi
    Suayib Yalcin
    Demetris Papamichael
    Miklós Wenczl
    Zrinka Mrsic-Krmpotic
    Einat Shacham-Shmueli
    Damir Vrbanec
    Regina Esser
    Werner Scheithauer
    Christoph C Zie-linski
    World Journal of Gastroenterology, 2010, 16 (25) : 3133 - 3143
  • [4] A randomized, open-label CECOG phase II study evaluating the efficacy and safety of FOLFOX6+cetuximab versus FOLFIRI plus cetuximab as first-line therapy in patients (pts) with metastatic colorectal cancer (mCRC)
    Ciuleanu, T. E.
    Kurteva, G.
    Ocvirk, J.
    Beslija, S.
    Koza, I.
    Papamichael, D.
    Vrbanec, D.
    Brodowicz, T.
    Scheithauer, W.
    Zielinski, C. C.
    JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (15)
  • [5] A randomized, open-label cecog phase II study evaluating the efficacy and safety of FOLFOX6+cetuximab and FOLFIRI plus cetuximab as first-line therapy in metastatic colorectal cancer (MCRC)
    Ciuleanu, T.
    Scheithauer, W.
    Kurteva, G.
    Ocvirk, J.
    Koza, I
    Papamichael, D.
    Vrbanec, D.
    Brodowicz, T.
    Beslija, S.
    Zielinski, C.
    ANNALS OF ONCOLOGY, 2008, 19 : 26 - 26
  • [6] COMPARISON OF FOLFOX6 PLUS CETUXIMAB WITH FOLFIRI PLUS CETUXIMAB AS FIRST-LINE THERAPY IN METASTATIC COLORECTAL CANCER (MCRC): A RANDOMIZED OPEN-LABEL PHASE II CECOG STUDY
    Beslija, S.
    Koza, I.
    Ocvirk, J.
    Ciuleanu, T.
    Kurteva, G.
    Papamichael, D.
    Vrbanec, D.
    Messinger, D.
    Brodowicz, T.
    Zielinski, C. C.
    ANNALS OF ONCOLOGY, 2008, 19 : 168 - 168
  • [7] First-line therapy with cetuximab followed by cetuximab plus folfiri in patients with metastatic colorectal cancer: KRAS mutation status correlates with clinical outcome
    Martinelli, E.
    Macarulia, T.
    Vega-Villegas, E.
    Rodriguez-Braun, E.
    Ciardiello, F.
    Ramos, F.
    Rivera, F.
    Stroh, C.
    Nippgen, J.
    Cervantes, A.
    Baselga, J.
    Tabernero, J.
    ANNALS OF ONCOLOGY, 2008, 19 : 25 - 25
  • [8] Cetuximab plus folfiri first-line in metastatic colorectal cancer (MCRC): The randomized phase III crystal trial
    Koehne, C.
    Zaluski, J.
    Chung, Rong C.
    Makhson, A.
    D'Haens, G.
    Pinter, T.
    Lim, R.
    Ruff, P.
    Rougier, P.
    Van Cutsem, E.
    ANNALS OF ONCOLOGY, 2007, 18 : VII21 - VII21
  • [9] The crystal study:: Assessment of the predictive value of KRAS status on clinical outcome in patients with mcrc receiving first-line treatment with cetuximab or cetuximab plus folfiri
    Van Cutsem, E.
    Lang, I
    D'haens, G.
    Moiseyenko, V
    Zaluski, J.
    Koehne, C.
    Folprecht, G.
    Tejpar, S.
    Shparyk, Y.
    Schlichting, M.
    Kisker, O.
    Stroh, C.
    Rougier, P.
    ANNALS OF ONCOLOGY, 2008, 19 : 17 - 18
  • [10] Correlation of KRAS status (wild type [wt] vs. mutant [mt]) with efficacy to first-line cetuximab in a study of cetuximab single agent followed by cetuximab plus FOLFIRI in patients (pts) with metastatic colorectal cancer (mCRC)
    Cervantes, A.
    Macarulla, T.
    Martinelli, E.
    Rodriguez-Braun, E.
    Ciardiello, F.
    Stroh, C.
    Nippgen, J.
    Baselga, J.
    Tabernero, J.
    JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (15)
12345